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Inflammatory bowel disease (IBD) is characterized by a chronic flaring inflammation of the gastrointestinal
tract. To determine disease activity, the inflammatory state of the colon should be assessed. Endoscopy in
patients with IBD aids visualization of mucosal inflammation. However, because the mucosa is fragile, there
is a significant risk of perforation. In addition, the technique is based on grading of the entire colon, which
is highly operator-dependent. An improved, noninvasive, objective magnetic resonance imaging (MRI) tech-
nique will effectively assess pathologies in the small intestinal mucosa, more specifically, along the colon,
and the bowel wall and surrounding structures. Here, dextran sodium sulfate polymer induced acute colitis in
mice that was subsequently characterized by multisection magnetic resonance colonography. This study
aimed to develop a noninvasive, objective, quantitative MRI technique for detecting mucosal inflammation in
a dextran sodium sulfate–induced colitis mouse model. MRI results were correlated with endoscopic and his-
topathological evaluations.
INTRODUCTION
Inflammatory bowel disease (IBD) encompasses 2 major forms of
intestinal inflammation—ulcerative colitis (UC) and Crohn’s dis-
ease (CD)—both of which are characterized by chronic exacer-
bations of inflammation in the gastrointestinal tract (1). IBD is
a global disease of increasing prevalence. More than 1 million
individuals in the USA and 2.5 million in Europe are estimated
to have IBD, with annual health-care costs of $6 billion and
€4.6–5.6 billion, respectively (2, 3). Patients with IBD experi-
ence clinical gastrointestinal indications, as well as chronic
emotional symptoms, that can severely reduce quality of life and
ability to work. Imaging techniques can play a key role in the
diagnosis and lifelong evaluation of patients with IBD. In par-
ticular, the development of noninvasive imaging techniques
that can perform the initial screening and diagnosis of IBD, in
particular, at early stages, will be of considerable value.
The clinical severity of IBD is usually proportional to the
extent of bowel involved and the intensity of the inflammation
process in the affected tissue (4). The inflammation in CD may
potentially extend to any part of the gastrointestinal tract,
whereas inflammation in UC extends from the rectum and in-
volves the distal part of the colon (5). The inflammatory process
in UC is typically confined to the innermost lining or mucosa
and may involve all of the gastrointestinal tract continuously,
whereas the inflammatory process in CD may involve all layers
of the intestine, but a “skip lesion” appears between the healthy
and affected tissue (6). The etiology of both diseases remains
unclear, although a combination of genetic, environmental, and
immunological factors contributes to disease initiation and
progression (7).
IBD is, in general, diagnosed on the basis of a combination
of clinical, pathological, radiological, endoscopic, and labora-
tory indications (8). To determined disease activity and tailor
IBD therapy, the inflammatory state of the colon should be
assessed. However, clinical features alone are neither sensitive nor
specific enough for grading lesion severity in IBD, and imaging
plays a key role in its diagnosis (9, 10). Endoscopy is the gold-
standard technique for diagnosis of IBD, aiding direct visualiza-
tion of the colonic mucosa, the target of the disease. Endoscopy
helps to identify inflammation, including its location and sever-
ity, and obtain biopsies needed to confirm the diagnosis. How-
ever, endoscopy is an invasive technique that requires patient
preparation and discomfort, and interpretation of its results is
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native, noninvasive imaging modalities are being explored to com-
plement endoscopy for diagnosis of IBD. Computed tomography
(CT) can be used to diagnose and evaluate the extent and severity of
inflammatory diseases in the small bowel and colon. However,
owing to the radiation exposure associated with CT, it is not a
useful imaging technique for multiple follow-up examinations af-
ter therapy, particularly in young patients (11). Also, CT suffers
from low diagnostic sensitivity for the early stages of UC (8).
Recently, magnetic resonance imaging (MRI) has emerged as
an important imaging modality for detecting morphologic changes
and inflammatory activity associated with IBD in both patients (11,
13-17) and animal models (8, 9, 18-21). MRI is a noninvasive
technique, using nonionizing radiation, which has equal or better
sensitivity than CT for imaging IBD (11). A significant advantage of
MRI is the existence of multiple, intrinsic contrast mechanisms that
may be used to highlight intestinal tissues with inflammation. In
contrast-enhanced, T1-weighted images, the degree of gadolinium
enhancement at the level of the colon wall correlates qualitatively
with disease activity (8, 15, 16). In a complementary manner,
T2-weighted (T2W) sequences highlight tissue–fluid content, and
are, therefore, sensitive to inflammation and thickening of the
colon wall. However, these findings are consistently observed in
only severe and active UC. In moderate and quiescent stages of UC,
no effect on the colon wall thickness is found (15), and current MRI
methods are not sensitive enough for robust detection of these
stages of UC. The development of robust, noninvasive imaging
protocols that can be performed repetitively to detect mucosal
inflammation and score the extent and severity of disease, in
particular at early stages, will be important for IBD diagnosis
and therapy.
The most commonly used animal models of IBD involve chem-
ically induced intestinal inflammation. Such models, which are
straightforward and generate a nearly immediate onset of inflam-
mation, display many important immunological and histopatho-
logical characteristics of IBDs seen in humans (6, 7). For exam-
ple, introducing dextran sodium sulfate (DSS) (2.5% wt/vol) in
drinking water for several days induces acute colitis in mice,
characterized by a variety of symptoms that are consistent with
colitis in patients, including, hyperemia, ulcerations, moderate-
to-severe submucosal edema, and lesions, accompanied by his-
topathological changes that include infiltration of granulocytes,
which are manifested in the form of bloody diarrhea (4). It is
generally believed that DSS is directly toxic to gut epithelial
cells of the basal crypts and affects the integrity of the mucosal
barrier (6, 7). Because of this direct toxicity, DSS causes ero-
sions, with complete loss of surface epithelium, and deformity in
the epithelial integrity, thereby increasing colonic mucosal per-
meability. DSS-induced UC appears to be more severe in the
distal colon, although it causes an increase in the production of
all proinflammatory cytokines in both midcolon and distal
colon (4).
Several groups have described magnetic resonance (MR) stud-
ies of DSS-treated mice. Melgar et al., established a rapid MRI
screening tool, based upon colon wall thickness and hyperinten-
sity in T2W images, for distinguishing between healthy and
DSS-treated mice (20). Using T1-weighted imaging and an iron
oxide-based ink solution, Walldorf et al., measured colon wall
thickness and were able to discriminate between healthy control
mice, DSS-colitis mice, and DSS-colitis mice treated with an anti-
inflammatory (21). In studies using T2W images and maps, Breyn-
aert et al., investigated bowel wall inflammation and fibrosis in
a murine model of IBD, with repeated cycles of DSS (1.5%–2%
wt/vol) designed to mimic the relapsing nature of the disease
(19). In the PG-PS rat model, Alder et al., showed that magne-
tization transfer MRI could differentiate fibrotic from inflamed
bowel (18). Although these MR studies demonstrated success in
distinguishing healthy from damaged, inflamed colon, none
displayed the sensitivity required for early-stage detection and
grading of IBD.
The aim of this study was to develop an improved, nonin-
vasive, in vivo MRI-based grading tool for quantifying IBD, on
a positional basis along the length of the colon, in a DSS-induced
murine model of colitis. We correlated MRI-derived metrics, based
on colon wall thickness and T2 maps of colon tissue, with endo-
scopic and histological features, in both normal colons and DSS-
treated colons. We also estimated the sensitivity of this new
MRI-based grading tool at different positions within the colon,
which will be important for early-stage diagnosis of IBD.
METHODOLOGY
Animals
Animal experiments were approved by the Weizmann Institute Ani-
mal Care and Use Committee following Israeli, US National
Institutes of Health, and European Commission guidelines. Eight-
week-old male C57BL/6 mice (n  26) were obtained from Envigo
(Rehovot, Israel). Mice were treated with 0%–2% (wt/vol) DSS (MP
Biomedicals; molecular weight, 36,000–50,000 Da) in drinking
water for 7 days, followed by 5 days of regular water (7). The
mice were divided into the following 5 groups: untreated (n  6),
0.5% DSS (n  5), 1% DSS (n  5), 1.5% DSS (n  5), and 2%
DSS (n  5) treated mice. Survival and changes in body weight
of the animals were monitored daily over the course of colitis
development. Mice were monitored throughout the experiment,
and any that showed extreme distress, became moribund, or lost
more than 20% of initial body weight were euthanized.
MRI
All mice were imaged on days 7 and 11 post DSS treatment.
Prior to imaging, animals were anesthetized using intramuscu-
lar injection of a mix of Domitor (Medetomidine, 1 mg/kg; Orion
Corporation, Espoo, Finland) and Ketamine (75 mg/kg; Veto-
quinol, Lure, France) and were administered successive warm
saline enemas (2 mL) to clear the colon of solid fecal material.
Two milliliters of perfluorinated oil (Fomblin Y LVAC 06/6 perfluo-
ropolyether oil; Sigma-Aldrich, St. Louis, MO) were introduced
into the colon via a rectal catheter consisting of microbore
tubing (20G cannula, Delta Med). The setup of the mice in the
MRI animal holder is shown in Figure 1A. At the end of the MRI
protocol, the anesthetized mice were injected intraperitoneally
with Antisedan (1 mg/kg; Orion Corporation).
MRI experiments were performed on 9.4 Tesla BioSpec Magnet
94/20 USR system (Bruker BioSpin Corporation, Billerica, MA)
equipped with a gradient coil system capable of producing
pulsed gradients of up to 40 G/cm in each of 3 orthogonal
directions. MR images were acquired using a quadrature vol-
ume coil with 35-mm inner diameter (Bruker). The T2 maps
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were acquired using multisection spin-echo imaging, with in-
terleaved sections and the following parameters: a repetition
delay of 3000 milliseconds, 16 time echo increments (linearly
from 10 to 160 milliseconds), matrix dimension of 256  128
(interpolated to 256  256) and 2 averages, corresponding to an
image acquisition time of 12 minutes 48 seconds. Fourteen
contiguous, 1-mm-thick sections, were acquired, with a field of
view of 3.0  2.5 cm2.
Endoscopy
Colonoscopy was performed on days 7 and 11 post DSS treat-
ment to monitor the severity of colitis. Colitis was scored by a
single rater according to the Murine Endoscopic Index of Colitis
Severity (MEICS), considering five factors: (i) thickening of the
colon wall; (ii) changes in vascular pattern; (iii) presence of
fibrin; (iv) mucosal granularity; and (v) stool consistency. Each
factor was scored with a value between 0 and 3. The cumulative
score ranged from 0 (no signs of inflammation) to 15 (signs of
very severe inflammation) (22). Healthy mice typically have
cumulative scores of 0–3.
Histopathology
On the day of sacrifice (day 11), the colons were removed and
their lengths measured. They were then fixed in 2.5% para-
formaldehyde solution overnight at 4°C, embedded in paraf-
fin, sectioned, and stained with hematoxylin and eosin (H&E).
H&E-stained tissue was examined in a blinded manner by a
gastrointestinal pathologist. Tissues were graded on a 0–4 scale
based on the parameters of inflammation severity (7), according
to the following scoring system: 0, no evidence of inflamma-
tion; 1, low level of inflammation with scattered infiltrating
mononuclear cells, 1–2 foci; 2, moderate inflammation with
multiple foci; 3, high level of inflammation with increased
vascular density and marked wall thickening; and 4, maximal
severity of inflammation with transmural leukocyte infiltration
and loss of goblet cells.
Image Analysis
All image analyses were performed using purpose-written
MATLAB (R2013B) scripts. Quantitative T2 maps were gen-
erated from multiecho, T2W images by fitting the multiecho
signal as a monoexponential decay. Colon walls were man-
ually segmented as hyperintense (compared with muscle tis-
sue) regions in T2W spin-echo images. T2 maps of the colon
were calculated on a pixel-by-pixel basis and overlaid on
T2W images. Two regions of interest were drawn on each
map, representing the inner (red) and outer (yellow) radii of
the colon (Figure 1B). In performing this analysis, we as-
sumed that the colon is circular in shape, and we extracted its
radius as the difference between the areas of the outer and
inner circles. Two parameters, the mean T2 value of the colon,
and the colon apparent thickness, were calculated for each
section. Results are presented on a section-by-section basis
and as average values across all sections.
Statistical Methods
The results are reported as mean  SD. Student t test was used
to compare means of 2 groups, with P  .05 defining statistical
significance.
Figure 1. In vivo mouse magnetic resonance imaging (MRI) colonoscopy experiment. Mice were set up in a dedicated
MRI animal holder (A). The length of the scanned colon was 1 cm. Histological sections were taken from 4 regions [in
red, sections (a)–(d)] of this area. The most distal portion of the colon is defined as (a) and the most proximal portion as
(d). T2 maps of the colon, calculated on a pixel-by-pixel basis, with selection of two regions of interest, yellow and red,
representing the outer and inner colon radii, respectively (B). Mean T2 value and apparent thickness were calculated for
each section of the colon.
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RESULTS
In Vivo MRI Colonoscopy of Untreated Mice
Multisection MR images were collected in a cohort of untreated
control mice, and revealed clear differences along the length of
the colon in these animals. T2 maps, shown in Figure 2A,
illustrate a trend of increasing T2, from distal to proximal end,
along the measured region of the colon. Quantitative measure-
ment of T2 values of the colon wall, plotted in Figure 2B, shows
significantly higher values in proximal vs distal regions (71  1
milliseconds for the most proximal image section vs 54  1
milliseconds for the most distal section). However, as shown in
Figure 2C, no significant differences were observed in mean
colon wall thickness along the length of the colon (0.50  0.07
mm for the most proximal image section vs 0.56  0.14 mm for
the most distal section).
Histological examination of untreated colon at 4 different
points along the measured colon confirmed the MRI colono-
scopic observation (Figure 2D). There were no signs of inflam-
mation or crypt damage and no variation in the thickness of the
colonic wall. Nonetheless, microscopic examination of the colon
at 4 different points along its length showed differences in tissue
architecture, consistent with the positional-dependent T2 values
measured in the MRI colonoscopy experiment. The thickness
of the muscular layer, in particular that of the circular layer,
decreases from distal to proximal (23). The diameter of the colon
is also dependent on the presence or absence of fecal pellets
[present in (c) and (d), but not in (a) or (b)].
In Vivo MRI Colonoscopy of 1% DSS-Induced Acute
Colitis
To induce colitis, a cohort of mice was treated with 1% DSS,
administered in drinking water for 7 days, followed by 5 days of
untreated water. These mice showed decreases in body weight of
4% and 9% at days 7 and 11, respectively. Ex vivo pathological
Figure 2. In vivo MRI colonoscopy of untreated mouse. T2 maps of representative, untreated colon at different sections
along the colon (A). The most distal part is labeled as 1 and the most proximal as 10. Colon wall mean T2 values
(B) and mean apparent thickness (C) as functions of section position along the colon are presented. Values are re-
ported as mean  SD. Hematoxylin and eosin (H&E)-stained transverse sections of control colon obtained from 4
different points (a–d) along the imaging area (1 cm) (D). The most distal part is shown in (a) and the most proxi-
mal part in (d).
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analysis showed significantly shorter colons, owing to inflam-
mation and edema, in the 1% DSS-treated mice (5.4  0.2 cm) vs
untreated controls (7.2  0.4 cm, P  .0001).
Figure 3 shows in vivo MRI data from a representative
untreated mouse (top row) and a 1% DSS-treated mouse at days
7 (middle row) and 11 (bottom row). Examples of T2-weighted
images, both full (Figure 3, A–C) and expanded (Figure 3, D–F)
and expanded T2 maps (Figure 3, G–I) are shown. In the T2-
weighted MR images, the signal of the colon wall of the 1%
DSS-treated mouse at days 7 and 11 is hyperintense compared
with that of the untreated mouse. Also, these images reveal a
significant change in the colon diameters of the treated mice at
day 11. T2 maps show higher T2 values for the DSS-treated
colon at days 7 and day 11 (yellow and red pixels) than for the
colon of an untreated mouse (blue pixels).
Table 1 shows mean colon T2 values and apparent colon
thickness, calculated from the T2 maps, as averages across all
image sections. The mean T2 values for colons from the 1%
DSS-treated mice were significantly higher on days 7 (83  15
milliseconds) and 11 (88  6 milliseconds) than for colons from
untreated mice (61  2 milliseconds, P  .05 and P  .0001 vs
post-DSS-treatment days 7 and 11, respectively). Although no
significant change in colon thickness was observed on post-
treatment day 7, an increase in the mean apparent colon thick-
ness after 1% DSS treatment was observed at day 11 (0.90 
0.07 cm) vs untreated colon (0.51  0.03 cm, P  .005).
Mean colon T2 values and thicknesses, calculated on a
section-by-section basis, are shown in Figure 4. Unlike un-
treated, control animals, mean T2 values of the colon wall in
mice treated with 1% DSS show little positional dependence, at
either day 7 or 11. Thus, because of the positional variation seen
in controls, changes in mean T2 in treated mice are more pro-
nounced in the distal part of the colon than in the proximal part
(Figure 4A). For example, increases in mean T2 values in the
most proximal imaging section were 22%  20% (day 7) and
18%  6% (day 11), while corresponding increases in the most
distal section were 44%  28% (day 7) and 66%  10% (day 11),
respectively. At day 11, there is a trend toward increased thick-
ness from distal-to-proximal positions within the colon (Figure
4B). Relative to controls, the effect of the DSS treatment on
mean apparent colon thickness is more pronounced in the prox-
imal portion of the colon (increase of 93%  45% for the most
proximal image section) than in the distal portion (62%  24%).
Evaluation of Dose-Dependent DSS-Induced Colitis by
Endoscopy, Histology, and MRI Colonoscopy
To characterize the dose dependence of DSS-induced colitis,
separate cohorts of mice were treated with 0.5%, 1%, 1.5%, or
2% DSS, administered in the drinking water for 7 days, followed
by 5 days of untreated water. Mice treated with 1.5% or 2% DSS





Control (n  6) 61.0  2.0 0.51  0.03
1% DSS—Day 7 83.3  15.4* 0.49  0.06
1% DSS—Day 11 88.3  5.8*** 0.90  0.07**
Note: The quantitative analysis allows calculation of mean colon T2
and colon thicknesses, as averages across all sections, in untreated
mice (n  6) and mice treated with 1% DSS on days 7 (n  5) and 11
(n  5). Values are mean  SD. *P  .05, **P  .005, and ***P 
.0001, Student 2-tailed t test.
Figure 3. In vivo colon MRI
quantification of untreated and
treated mice. The T2-weighted
(T2W) magnetic resonance (MR)
images (A–C), and corresponding
expanded regions, showing T2W
images (D–F) and T2 maps (G–I),
of a representative untreated
mouse and a mouse treated with
1% dextran sodium sulfate (DSS),
on post-treatment days 7 and 11,
respectively.
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showed a decrease in body weight of up to 24% on day 7 and up
to 31% on day 11. Ex vivo analysis revealed significantly
shorter colons in mice treated with 1%, 1.5%, or 2% DSS-treated
mice [average colon lengths, 5.4  0.2 (P  .00003), 5.5  1.0
(P  .004), and 5.3  1.1 cm (P  .005), respectively vs
untreated mice (7.2  0.4 cm). No significant differences were
observed between the untreated and 0.5% DSS-treated colons
(7.2  0.4 cm). Mice treated with 0.5%, 1%, 1.5% or 2% DSS
were also characterized, in detail, by endoscopy, histology, and
MRI colonoscopy.
As described in Methods/Endoscopy, the endoscopy scoring
is based on colon wall thickening, vascularity, presence of
fibrin, mucosal granularity, and stool consistency. Each param-
eter receives a score of 0, 1, 2, or 3, and the composite endoscopy
score is the sum of all of the parameter scores. The endoscopy
scores for the 0.5%, 1%, 1.5%, and 2% DSS-treated mice were
2.5  0.6, 3.3  1.4, 8.6  1.3, and 10.3  0.6 at day 7, and 4.3 
0.8, 10.0  1.2, 10.8  1.3, and 13.7  0.6 at day 11, respec-
tively. P-values calculated by comparing these values with en-
doscopy scores for the untreated groups were all .001. On both
days 7 and 11, endoscopy scores were higher for higher levels of
DSS treatment, and scores increased between days 7 and 11 for
all treatment groups.
Figure 5A shows representative H&E-stained sections and
corresponding endoscopy images of the colon on day 11 for
mice treated with 0.5%, 1%, 1.5%, and 2% DSS. Colons of
untreated mice had intact mucosa, as shown in Figure 2D. There
was neither endoscopic nor microscopic evidence of colitis in
the 0.5% DSS group. In colons of the 1%, 1.5%, and 2% DSS
groups, there was extensive to diffuse crypt loss and ulceration,
accompanied by severe submucosal edema (arrows in Figure 5A)
and variable inflammatory infiltration. In the 1.5% and 2%
DSS-treated mice, there was free blood in the intestinal lumen
(marked with *). As detailed in Methods/Histopathology, mice
were scored on a histology scale ranging from 0 (no evidence of
inflammation) to 4 (severe inflammation with transmural leu-
kocyte infiltration and loss of goblet cells). The histology scores
for the 0.5%, 1%, 1.5%, and 2% DSS-treated mice were 0.2 
0.3, 2.1  0.8, 3.1  0.5, and 4.0  0.1, respectively, on day 11.
A good correlation was found between the in vivo endoscopy
scores and the histology scores (Figure 5B).
Representative T2 maps from mice treated with 0.5%, 1%,
1.5%, or 2% DSS are shown in Figure 6A. The image intensities
of the colons of these mice were elevated at both days 7 and 11.
The maps of the 0.5% DSS group were similar to those of
untreated controls. Mean colon T2 values and apparent colon
thicknesses, extracted from the T2 maps and averaged across all
imaging sections, are shown in Figure 6B and 6C, respectively.
DSS treatment, at levels of 1%–2%, caused significant increases
in mean colon T2 values at days 7 and 11, whereas no signif-
icant differences were measured at either time point for mice
treated with 0.5% DSS. Apparent colon thickness followed a
different pattern of response to DSS treatment. On day 7, no
significant changes in colon thickness were observed at any
level of DSS treatment, whereas on day 11, significant in-
creases (P  .02) in wall thickness were observed for mice
treated with 1% or greater DSS.
Mean colon T2 values and mean apparent colon thickness
parameters were also calculated on a section-by-section basis
for each DSS level (Figure 7). For all levels of DSS treatment,
section-by-section analysis of apparent colon thickness showed
no significant changes on day 7 (Figure 7A). No changes were
observed on day 11 for the 0.5% DSS-treated mice. However, at
all section positions, there was a significant increase in the mean
apparent colon thickness on day 11 for all mice treated with
0.5% DSS (Figure 7B), and a significantly higher mean appar-
ent colon thickness was observed for all mice treated with
0.5% DSS. Somewhat surprisingly, the highest mean apparent
colon thickness was found in 1% DSS-treated mice.
Figure 4. Quantitative analysis of T2 maps calculated from a section-by-section analysis of untreated and treated mice.
Mean colon T2 values (A), mean apparent colon thickness as function of section position along the colon in the un-
treated colon (n  6), and treated mice with 1% DSS on day 7 (n  5) and 11 (n  5) (B). Values are reported as
mean  SD. *P  .05 Student 2-tailed t test, for all section positions, for both mean colon T2 values, and mean appar-
ent colon thickness, except for the mean colon T2 values at a section position of 7 mm.
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On day 7, mean colon T2 values for the cohort of 0.5%
DSS-treated mice were very similar to those for the untreated
group (Figure 7C), with the same trend of increasing T2, proxi-
mal to distal, observed in both groups. On day 11, the same
proximal-to-distal trend was seen, although a small but signifi-
cant increase in mean T2 values was observed in the 0.5% DSS-
treated mice (Figure 6D). In animals treated with 0.5% DSS, mean
colon T2 values increased significantly at all section positions on
both day 7 and day 11. The graphs in Figure 7, C–D also show that
the effect of DSS treatment (0.5%) is more pronounced in the
distal part of the colon, in particular at day 11.
A Pearson product–moment correlation coefficient was com-
puted to assess the relationship between the MR colonography
parameters (average T2 value and colon thickness across all
sections) and endoscopy and histology findings at day 11 in the
1% DSS-treated mice. The correlations between average T2
value and measures of endoscopy and histology were significant
(Pearson r  0.77 and 0.66, respectively), whereas the corre-
sponding correlations between average colon thickness and
these same measures were much weaker (Pearson r  0.59 and
0.50, respectively).
DISCUSSION
UC is a serious and often debilitating condition, with significant
long-term consequences for patients. Early detection of UC in-
creases treatment options and improves outcomes, but robust
techniques for early detection and accurate monitoring of in
vivo treatment response in UC patients are lacking. This study
aimed to show the use of a noninvasive MR imaging tech-
nique, T2 mapping, for identifying and quantitatively grad-
ing UC in a chemically induced mouse model. We showed
clearly that our T2-based MR experiments and analysis can
provide a quantitative measure of UC inflammation on a
positional (ie, section-by-section) basis along the colon. Our
MRI findings were validated by endoscopic evaluation and
colon biopsies. The quantitative information about colitis
activity and colon wall thickness derived from noninvasive
MR experiments can be readily translated to the clinic for
improved early detection of UC and monitoring of the effi-
cacy of treatment in UC patients.
As noted earlier, MRI-derived metrics, including measures
of colon wall thickness and inflammation and gadolinium (con-
trast-agent) enhancement, have established MRI as an impor-
tant, noninvasive imaging modality for detecting morphologic
changes and inflammatory activity associated with IBD. How-
ever, these findings are consistently observed in only severe and
active UC. In moderate and quiescent stages of UC disease, no
effect on the colon wall thickness is found (15), and current MRI
methods are not sensitive enough for robust detection of UC.
Herein, we show quantitative T2 mapping, including both posi-
tional dependence and average along the colon, as a method for
improving evaluation of the extent and severity of UC, thereby
improving early, accurate diagnosis.
Our initial experiments focused on the characterization of
healthy, untreated colon. As expected, no significant differences
were found in the mean colon wall thickness along the length of
the colon. Somewhat surprisingly, T2 mapping revealed higher
T2 values in proximal vs distal regions, findings that correlated
with positionally dependent differences in tissue architecture
and cellular composition. These findings were mirrored in
differences observed histologically. The mouse basic bowel
wall structure includes the mucosa, submucosa, muscularis, and
serosa. The mouse muscularis propria has inner circular and
outer longitudinal layers. The mouse cecal muscular layers are
thinner than the more distal colon muscular layers. The muscu-
lar tunics increase in thickness progressively in the distal and
Figure 5. H&E-stained colon sections, and corresponding endoscopy images, taken on day 11, from treated mice with
0.5%–2% DSS (A). Correlation between histology scores and colonoscopy scores as a function of the DSS dose (%).
Values are reported as mean  SD (B).
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descending colon. The mucosa of mouse proximal colon has
transverse folds that are longer than those present in the cecum.
Mouse midcolonic mucosa is flat with no mucosal folds. The
distal colon of the mouse has longitudinal mucosal folds.
In UC in human, ulcers gradually spread upward from their
points of origin, until the entire colon is involved. Thus, a method
that can improve diagnostic sensitivity on a positional basis has
direct translational importance. Our MRI-derived metrics, which
showed sensitivity to positionally dependent colon thickening
and inflammation, may have clinical relevance to the diagnosis
of UC, in particular at early stages of the disease.
One of the significant differences between this work and
earlier studies is the examination of the effects of lower levels of
DSS treatment. Although most previous experiments were per-
formed with high dosage (2% wt/vol) of DSS in the drinking
water (7-9, 20), here, we examined mice treated with as little as
0.5% DSS. The development of imaging markers in these lower-
dosage studies has potential importance for the early-stage
diagnosis of IBD. Below 1% DSS, our T2-based, MR colonog-
raphy tool was unable to detect changes in the colon, an
observation that was consistent with colonoscopy and, in
particular, histology in these same mice. However, in 1%
DSS-treated animals, the in vivo MRI-grading tool revealed
significant inflammation at post-treatment days 7 and 11, as
reflected by increases in mean colon T2 of 36% and 45%,
respectively. Section-by-section analysis of T2 maps showed
that the inflammation was positionally dependent along the
colon, being more pronounced distally than proximally. This
finding is consistent with a report by Suzuki et al., that the
severity of inflammation, measured by histology, was the
greatest in the distal region of the colon in a DSS colitis
mouse model initiated with azoxymethane (24).
Figure 6. DSS dosage response. The T2 maps of representative treated mice with different DSS ratio from 0.5% to 2%
on day 7 and 11 (A). Quantitative analysis of T2 maps, as an average value across all sections of untreated and
treated mice, at different DSS ratios. Mean colon T2 values (B), Mean apparent colon thickness in untreated (0% DSS)
colon (n  6), and treated mice with 0.5%–2% DSS on day 7 (n  5) and 11 (n  5) (C). Values are reported as
mean  SD. *P  .05 Student 2-tailed t test.
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Of note, MRI-derived colon wall thickness was unaffected
at post-treatment day 7 following 1% DSS administration.
Thus, T2 mapping proved more sensitive to early DSS-in-
duced pathology than wall thickness. By post-treatment day
11, the colon wall thickness was increased, with greater
thickening of the wall in the proximal portion of the colon
than in the distal portion.
In the current study, colonoscopy and histology scores at
post-treatment day 11 increased with increasing DSS dose
(above 0.5% DSS). MRI findings at days 7 and 11 provided
important insights into the dose dependence of DSS-induced
injury. Based upon observed increases in T2, DSS dose-depen-
dent colonic inflammation was similar at days 7 and 11 for all
DSS levels 0.5%, and showed little positional dependence
along the colon. However, compared with T2 values for normal
colon, T2 increases for DSS levels 0.5% were greater in the
distal region of the colon.
A different pattern was observed for MRI-derived colon
wall thickness as a function of DSS level. At post-treatment day
7, colon wall thickness for all DSS levels was similar to normal
colon, and was positionally independent. By contrast, at day 11,
significant increases in colon wall thicknesses were observed
for DSS levels 0.5%. Again, no positional dependence of wall
thickness was observed. Interestingly, the greatest increase in
the colon wall thickness at day 11 was observed for mice treated
with 1% DSS. In total, our MRI results suggest that treating mice
with 1% DSS in drinking water for 7 days, followed by 5 days of
regular water, produces the most severe colitis, with better
reproducibility and lower mortality than higher doses of DSS.
The use of sensitive T2 mapping-based MR colonography,
together with improved reproducibility and lower mortality of
the murine 1% DSS-induced colitis model, will provide new
opportunities for studying therapeutic drugs to combat the dis-
ease. MR imaging will allow longitudinal monitoring of thera-
peutic response and improve sensitivity for detecting healing at
specific locations along the colon.
In summary, findings from the present study suggest that
the established, T2 mapping-based MR colonography tool can
be used to reliably characterize colon damage in a chemically
induced mouse model. It was demonstrated clearly that colon
Figure 7. Quantitative analysis of T2 maps calculated from a section-by-section analysis of untreated and treated mice
at different DSS ratio. Mean apparent colon thickness values in untreated (0% DSS) colon (n  6) and treated mice with
0.5%–2% DSS on day 7 (A) (n  5) and 11 (B) (n  5). Mean colon T2 values in untreated (0% DSS) colon (n  6)
and treated mice with 0.5%–2% DSS on day 7 (C) (n  5) and 11 (D) (n  5). Values are reported as mean  SD.
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thickness, measured via conventional, T2-weighted sequences,
is insufficient for assessing disease severity, in particular, in the
early stages. Mean T2 value, an MR biomarker of inflammation,
was found to be quantitative and sensitive to disease severity.
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